|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 194.4 USD | +2.03% |
|
-1.92% | -24.88% |
| Apr. 19 | Needham Adjusts Price Target on Biogen to $294 From $300 | MT |
| Apr. 19 | BMO Capital Adjusts Price Target on Biogen to $260 From $285, Outperform Rating Kept | MT |
April 22 (Reuters) - Biogen Inc said on Friday it has notified the European Medicines Agency of its decision to withdraw the marketing authorization application for its troubled Alzheimer's drug, aducanumab. (Reporting by Manas Mishra in Bengaluru; Editing by Arun Koyyur)
| 1st Jan change | Capi. | |
|---|---|---|
| -24.88% | 27.69B | |
| -5.99% | 84.46B | |
| +2.76% | 40.85B | |
| +53.61% | 24.28B | |
| -8.08% | 17.09B | |
| -33.74% | 13.67B | |
| -16.63% | 11.86B | |
| -11.19% | 11.79B | |
| -2.25% | 8.07B | |
| +1.05% | 7.51B |
BIOGEN INC. 
